A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This study seems to be observational — tracking how tislelizumab is used in real-world practice rather than testing a new drug — so does that mean my treatment decisions would still be entirely guided by what my doctor thinks is best for me, rather than a study protocol?
2. 2Since this trial is measuring things like how long patients stay on tislelizumab and how often doses are adjusted or stopped, would joining this study require me to do any extra clinic visits, tests, or data collection beyond my normal care?
3. 3For my specific diagnosis — whether it's advanced non-small cell or extensive-stage small cell lung cancer — is tislelizumab already an established treatment option in Europe, and how does it compare to other immunotherapy approaches my care team might consider?
4. 4The study is tracking how much time passes between diagnosis and starting the first dose, which makes me wonder — is there any urgency to starting treatment soon, and could enrolling in this observational study affect the timing of when I begin?
5. 5Are there any standard treatment paths I should consider first before we discuss whether participating in this real-world data study makes sense for my situation?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.